by Raynovich Rod | Nov 19, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, Macro
Bull Market Intact But Momentum Stocks Taking Hits Most of you know the game. Buy stocks with headline news, new business models, increasing RSI and charts that scream momentum. Examples proliferate: Aegerion (AEGR), Celldex (CLDX), Netflix (NFLX), Tesla (TSLA), 3D...
by Raynovich Rod | Nov 15, 2013 | 2025 Rayno Biopharmaceuticals Portfolio
Vertex (VRTX $67) Contrarian Trade Working Vertex is one of the worse performing large cap biotechs over 6 mos. is getting boosted on a $152M royalty deal. “Risk-On “Mode in Biotech Stocks Biotech stocks continue to find buyers with the IBB ($211.70)...
by Raynovich Rod | Nov 11, 2013 | Biopharmaceuticals
Biotech Stocks Perk Up on Shire/ViroPharma Merger Sweet Spot of The Market- Mid-Caps With Sales Growth One of the core Rayno Biopharmaceutical stock picks is up 25% to $49.37 in a $4.2B deal. ViroPharma, Inc. is a rare disease drug Company whose commercial product...
by Raynovich Rod | Nov 6, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Strong Jobs Report Boosts Market–Treasuries Sell -Off with 10 Year up to 2.74% Volatile Week Finds Buyers-Technical Levels Hold 11/8/13 9:45 a Biotechnology stocks rebounded today with the IBB up 3% to $203.86. The sector hit a major downdraft yesterday but we...
by Raynovich Rod | Nov 5, 2013 | 2025 Rayno Biopharmaceuticals Portfolio
Biotech Remains Strong But Momentum Is Easing Biotechnology stocks were positive today but major ETFs mixed with the FBT ($63.82) off 1.45%. Profit taking has hit some high fliers (AEGR,INCY) and many of our portfolio stocks are off their recent highs. Small and...
by Raynovich Rod | Nov 4, 2013 | 2025 Rayno Biopharmaceuticals Portfolio
Updated 2/11/15 see chart below Rayno 2013 Picks Outperform Biotechnology Indices and Funds Biopharmaceutical stocks hit all time highs in 2013 with major ETFs up as follows YTD: FBT ($65) up 41%, IBB ($206) up 50%, and XBI ((%120) up 36%. The Five Star Fidelity...
by Raynovich Rod | Oct 30, 2013 | 2025 Rayno Biopharmaceuticals Portfolio
Profit Taking Continues With Speculative Biotech Stocks Many of you who trade biopharmaceutical stocks know that $1B may be considered a small cap stock. As we mentioned in yesterday’s post there is weakness in many high flying biotech stocks compared to the...
by Raynovich Rod | Oct 29, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Dow, S&P and Biotech Sector Hit All Time Highs NASDAQ Still 1000+Pts Under 2000 High Levels After a 10% sell-off in early October many large cap biopharmaceutical and diagnostic stocks are at new highs with the major indices at or near their October highs. The...
by Raynovich Rod | Oct 9, 2013 | Biopharmaceuticals
Are Biotech Valuations in the “Bubblet” Phase? In September of 2013 we wrote about the valuations of biotechnology companies from an M&A perspective after the acquisition of Onyx Pharmaceuticals (ONXX) by Amgen at a price of $10.4B. We will attempt to...
by Raynovich Rod | Oct 7, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Our Indicators Flash a Caution Signal Today No Change in Portfolio Picks If you are not at 10% cash in your biotechnology portfolio it is time to take profits or hedge your portfolio. If your biotech stock did not hit a new high last week you may want to sell it. Risk...
